CervoMed Inc. Files 8-K

TL;DR

CervoMed filed an 8-K on 12/10/24. Check it for updates.

AI Summary

CervoMed Inc. filed an 8-K on December 10, 2024, reporting on other events and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing provides an update on CervoMed Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains updates on corporate events and financial statements, not usually indicative of immediate high risk.

Key Numbers

• 001-37942 — Commission File Number (Identifies the company's SEC filing history.)
• 30-0645032 — I.R.S. Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• Diffusion Pharmaceuticals Inc. (company) — Former Company Name
• RestorGenex Corp (company) — Former Company Name
• Stratus Media Group, Inc (company) — Former Company Name
• 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (location) — Principal Executive Office Address

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20241209_8k.htm (8-K) — 29KB
• ex_755525.htm (EX-99.1) — 19KB
• ex_755526.htm (EX-99.2) — 9KB
• crvo.jpg (GRAPHIC) — 5KB
• slide00.jpg (GRAPHIC) — 47KB
• slide01.jpg (GRAPHIC) — 114KB
• slide02.jpg (GRAPHIC) — 67KB
• slide03.jpg (GRAPHIC) — 75KB
• slide04.jpg (GRAPHIC) — 54KB
• slide05.jpg (GRAPHIC) — 45KB
• slide06.jpg (GRAPHIC) — 54KB
• slide07.jpg (GRAPHIC) — 60KB
• slide08.jpg (GRAPHIC) — 55KB
• slide09.jpg (GRAPHIC) — 73KB
• slide10.jpg (GRAPHIC) — 57KB
• slide11.jpg (GRAPHIC) — 55KB
• slide12.jpg (GRAPHIC) — 47KB
• 0001437749-24-037053.txt ( ) — 1308KB
• crvo-20241210.xsd (EX-101.SCH) — 3KB
• crvo-20241210_def.xml (EX-101.DEF) — 11KB
• crvo-20241210_lab.xml (EX-101.LAB) — 15KB
• crvo-20241210_pre.xml (EX-101.PRE) — 11KB
• crvo20241209_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Press Release On December 10, 2024, CervoMed Inc. (the "Company") issued a press release announcing topline data from its RewinD-LB Phase 2b clinical trial in patients with dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Corporate Presentation Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations" and a copy of which is attached as Exhibit 99.2 hereto. Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission ("SEC") and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise su

01 Other Events

Item 8.01 Other Events The information set forth in the first, third, and fifth paragraphs of the Company's press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 7.01 is furnished and not filed: Exhibit No. Description 99.1 Press Release, issued December 10, 2024. 99.2 Corporate Presentation of CervoMed Inc. dated December 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 10, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR